



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON

July 28, 2005

May C. Jereff
ATTORNEY FOR APPLICANT

July 28, 2005
DATE

Attorney Docket No. P32286

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackler et al. July 28, 2005
Serial No.: 10/019,355 Group Art Unit No.: 1625
Filed: March 22, 2002 Examiner: P.L. Morris
For: Thiazolidinedione Derivative and Its Use as Antidiabetic

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.


The documents cited herein are listed on the enclosed PTO Form 1449.
Copies of each are enclosed.

This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Serial No.: 10/019,355
Group Art Unit No.: 1625


Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Kathryn L. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5012
Facsimile (610) 270-5090
n:\kls\cases\p32286\supplementalids.doc



Sheet 1 of 1

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P32286SERIAL NO.
10/019,355**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Blackler et al.FILING DATE
March 22, 2002GROUP
1625**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 01/82867	11/8/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Phadnis et al., Identification of Drugs in Pharmaceutical Dosage Forms by X-Ray Powder Diffractometry, <i>Journal Pharmaceutical and Biomedical Analysis</i> , Vol. 15, pp. 929-943 (1997)
	Chakravarty et al., Crystal Forms of Tolbutamide from Acetonitrile and 1-Octanol: Effect of Solvent, Humidity and Compression Pressure, <i>International Journal of Pharmaceutics</i> , Vol. 288, pp. 33-348 (2005)
	Cantello et al., The Synthesis of BRL49653 – A Novel and Potent Antihyperglycaemic Agent, <i>Bioorganic & Medical Chemistry Letters</i> , Vol. 4, No. 10, pp. 1181-1184 (1994)
	Concise Encyclopedia Chemistry, pp. 872-873 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.